`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MYLAN PHARMACEUTICALS INC.
`
`Petitioner
`
`v.
`
`YEDA RESEARCH AND DEVELOPMENT CO. LTD.
`
`Patent Owner
`
`Case No. IPR2015-00644
`
`Patent No. 8,399,413
`
`PATENT OWNER’S MOTION FOR PRO HAC VICE ADMISSION OF
`NICHOLAS K. MITROKOSTAS UNDER 37 C.F.R. § 42.10(c)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case No. IPR2015-00644
`
`I.
`
`STATEMENT OF THE PRECISE RELIEF REQUESTED
`
`Pursuant to the Board’s “Notice of Filing Date Accorded to Petition and
`
`Time for Filing Patent Owner Preliminary Response,” dated February 25, 2015
`
`(Paper No. 5), authorizing the parties to file motions for pro hac vice admission
`
`under 37 C.F.R. § 42.10(c), Patent Owner Yeda Research and Development Co.
`
`Ltd. respectfully requests that the Board allow Nicholas K. Mitrokostas to appear
`
`pro hac vice on its behalf in this proceeding. Petitioner has stated that it will not
`
`oppose this motion.
`
`II. REASONS THE REQUESTED RELIEF SHOULD BE GRANTED
`As set forth in the Statement of Material Facts below, and as required by 37
`
`C.F.R. § 42.10(c), Patent Owner has demonstrated good cause to admit Mr.
`
`Mitrokostas pro hac vice in this proceeding. In particular, Patent Owner’s lead
`
`counsel is a registered practitioner, and Mr. Mitrokostas is an experienced
`
`litigating attorney having an established familiarity with the subject matter at issue
`
`in this proceeding.
`
`Furthermore, this motion is being filed more than twenty one days after
`
`service of the petition; includes a statement of facts showing good cause for the
`
`Board to recognize Mr. Mitrokostas pro hac vice; and is being filed concurrently
`
`with Exhibit 2138, the Declaration of Nicholas K. Mitrokostas in Support of Patent
`
`Owner’s Motion for Pro Hac Vice Admission of Nicholas K. Mitrokostas
`
`
`
`
`1
`
`
`
`Case No. IPR2015-00644
`
`(“Mitrokostas Decl.”), all in accordance with the “Order Authorizing Motion for
`
`Pro Hac Vice Admission” in Unified Patents, Inc. v. Parallel Iron, LLC, IPR2013-
`
`00639, Paper 7 at 3 (P.T.A.B. Oct. 15, 2013).
`
`III. STATEMENT OF MATERIAL FACTS
`1. 37 C.F.R. § 42.10(c) provides that “[t]he Board may recognize counsel pro
`
`hac vice during a proceeding upon a showing of good cause, subject to the
`
`condition that lead counsel be a registered practitioner and to any other
`
`conditions as the Board may impose. For example, where the lead counsel is a
`
`registered practitioner, a motion to appear pro hac vice by counsel who is not a
`
`registered practitioner may be granted upon showing that counsel is an
`
`experienced litigating attorney and has an established familiarity with the subject
`
`matter at issue in the proceeding.”
`
`2. Elizabeth J. Holland, lead counsel for Patent Owner Yeda Research and
`
`Development Co. Ltd. in this proceeding, is a registered practitioner holding
`
`Registration No. 47,657.
`
`3. As set forth in the Mitrokostas Decl., Mr. Mitrokostas is an experienced
`
`litigating attorney. Specifically, Mr. Mitrokostas has over a decade of experience
`
`representing clients in patent litigations, primarily in the chemical arts, in United
`
`States district courts and the Court of Appeals for the Federal Circuit.
`
`(Mitrokostas Decl., ¶¶ 2-3). Mr. Mitrokostas also has over a decade of
`
`
`
`
`2
`
`
`
`Case No. IPR2015-00644
`
`experience litigating cases on behalf of the Patent Owner and Teva entities, both
`
`generally and in litigations related to GA and Copolymer 1. (Mitrokostas Decl.,
`
`¶¶ 5-7).
`
`4. Mr. Mitrokostas also has an established familiarity with the precise subject
`
`matter at issue in this proceeding. Petitioner and Patent Owner are currently
`
`involved in district court litigation involving U.S. Patent No. 8,399,413 (“the
`
`’413 patent”), the patent at issue in this proceeding, against Petitioner and several
`
`other defendants in Teva Pharmaceuticals USA, Inc. et al. v. Mylan
`
`Pharmaceuticals Inc. et al., Civil Action No. 1:14-cv-01278-GMS (D.Del.)
`
`(consolidated as In re Copaxone 40 MG Consolidated Cases, Case No. 1:14-cv-
`
`01171-GMS (D. Del.)), as well as in Teva Pharmaceuticals USA, Inc. et al. v.
`
`Mylan Pharmaceuticals Inc. et al., Case No. 1:14-cv-00167-IMK (N.D.W.Va).
`
`Mr. Mitrokostas is litigation counsel for Teva Pharmaceuticals USA, Inc., Teva
`
`Pharmaceutical Industries Ltd., Teva Neuroscience, Inc. and Yeda Research and
`
`Development Co., Ltd., in these litigations. In the course of this representation,
`
`he has developed a strong familiarity with the ’413 patent, its prosecution history,
`
`the general subject matter to which the ’413 patent is directed, and the prior art
`
`references relied upon by Petitioner in support of its invalidity grounds in this
`
`proceeding. (Mitrokostas Decl., ¶ 8). Additionally, Mr. Mitrokostas has
`
`
`
`
`3
`
`
`
`Case No. IPR2015-00644
`
`thoroughly reviewed the Petition and accompanying Exhibits submitted in this
`
`proceeding. (Id.).
`
`5. Mr. Mitrokostas has attested to the each of the requirements set forth in
`
`paragraph 2(b)(i)-(viii) of the “Order Authorizing Motion for Pro Hac Vice
`
`Admission” in Case IPR2013-00639, Paper 7 at 3. (Mitrokostas Decl., ¶¶ 3, 4, 6-
`
`8, 9-13).
`
`IV. CONCLUSION
`In view of the foregoing, Patent Owner respectfully submits that the
`
`requirements of 37 C.F.R. § 42.10(c) have been satisfied, and requests an Order
`
`permitting Nicholas K. Mitrokostas to appear pro hac vice on its behalf in this
`
`proceeding.
`
`
`
`Dated: December 21, 2015
`
`Respectfully submitted,
`
`
`
`/Elizabeth J. Holland/
`Elizabeth J. Holland (Reg. No. 47,657)
`Goodwin Procter LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`Tel: 212-813-8800
`Fax: 212-355-3333
`
`Counsel for Patent Owner Yeda Research
`and Development Co. Ltd.
`
`
`
`
`4
`
`
`
`
`
`CERTIFICATION OF SERVICE
`
`The undersigned hereby certifies that “PATENT OWNER’S MOTION FOR
`
`PRO HAC VICE ADMISSION OF NICHOLAS K. MITROKOSTAS UNDER 37
`
`C.F.R. § 42.10(c),” and “EXHIBIT 2138- DECLARATION OF NICHOLAS K.
`
`MITROKOSTAS IN SUPPORT OF PATENT OWNER’S MOTION FOR PRO
`
`HAC VICE ADMISSION OF NICHOLAS K. MITROKOSTAS UNDER 37
`
`C.F.R. § 42.10(c)” were served electronically via e-mail on December 21, 2015 on
`
`the following:
`
`Jeffrey W. Guise
`
`jguise@wsgr.com
`
`Brandon M. White
`
`BMWhite@perkinscoie.com
`
`Shannon Bloodworth
`
`sbloodworth@perkinscoie.com
`
`David Anstaett
`
`DAnstaett@perkinscoie.com
`
`Richard Torczon
`
`rtorczon@wsgr.com
`
`
`
`Dated: December 21, 2015
`
`/Eleanor M. Yost/
`
`
`
`
`
`
`
`
`
`Eleanor M. Yost